Goldman Sachs Group Inc F Star Therapeutics, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $706 Billion
 - Q2 2025
 
Call Options
	  0 transactions
	
  | Quarter | Operation | Price Per call | calls change | calls Held | SEC Form | 
|---|
Others Institutions Holding FSTX
# of Institutions
3Shares Held
44.7KCall Options Held
0Put Options Held
0About F-star Therapeutics, Inc.
- Ticker FSTX
 - Exchange NASDAQ
 - Sector Healthcare
 - Industry Biotechnology
 - Shares Outstandng 21,584,700
 - Description
 - F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck c...